Your browser doesn't support javascript.
IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study.
Shojaei, Maryam; Shamshirian, Amir; Monkman, James; Grice, Laura; Tran, Minh; Tan, Chin Wee; Teo, Siok Min; Rodrigues Rossi, Gustavo; McCulloch, Timothy R; Nalos, Marek; Raei, Maedeh; Razavi, Alireza; Ghasemian, Roya; Gheibi, Mobina; Roozbeh, Fatemeh; Sly, Peter D; Spann, Kirsten M; Chew, Keng Yih; Zhu, Yanshan; Xia, Yao; Wells, Timothy J; Senegaglia, Alexandra Cristina; Kuniyoshi, Carmen Lúcia; Franck, Claudio Luciano; Dos Santos, Anna Flavia Ribeiro; de Noronha, Lucia; Motamen, Sepideh; Valadan, Reza; Amjadi, Omolbanin; Gogna, Rajan; Madan, Esha; Alizadeh-Navaei, Reza; Lamperti, Liliana; Zuñiga, Felipe; Nova-Lamperti, Estefania; Labarca, Gonzalo; Knippenberg, Ben; Herwanto, Velma; Wang, Ya; Phu, Amy; Chew, Tracy; Kwan, Timothy; Kim, Karan; Teoh, Sally; Pelaia, Tiana M; Kuan, Win Sen; Jee, Yvette; Iredell, Jon; O'Byrne, Ken; Fraser, John F.
  • Shojaei M; Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia.
  • Shamshirian A; Centre for Immunology and Allergy Research, the Westmead Institute for Medical Research, Westmead, NSW, Australia.
  • Monkman J; Department of Medicine, Sydney Medical School Nepean, Nepean Hospital, University of Sydney, Penrith, NSW, Australia.
  • Grice L; Gastrointestinal Cancer Research Centre, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Tran M; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Tan CW; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
  • Teo SM; School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.
  • Rodrigues Rossi G; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
  • McCulloch TR; The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.
  • Nalos M; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
  • Raei M; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
  • Razavi A; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Ghasemian R; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Gheibi M; Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia.
  • Roozbeh F; Gastrointestinal Cancer Research Centre, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Sly PD; Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Spann KM; Antimicrobial Resistance Research Centre, Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran.
  • Chew KY; Student Research Committee, School of Allied Medical Sciences, Mazandaran University of Medical Science, Sari, Iran.
  • Zhu Y; Mazandaran University of Medical Sciences, Sari, Iran.
  • Xia Y; Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia.
  • Wells TJ; Centre for Immunology and Infection Control, Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
  • Senegaglia AC; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
  • Kuniyoshi CL; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
  • Franck CL; School of Science, Edith Cowan University; School of Biomedical Science, University of Western Australia, Perth, WA, Australia.
  • Dos Santos AFR; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • de Noronha L; Complexo Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
  • Motamen S; Core for Cell Technology, School of Medicine, PontifìciaUniversidade Católica do Paraná, Curitiba, Brazil.
  • Valadan R; Complexo Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
  • Amjadi O; Core for Cell Technology, School of Medicine, PontifìciaUniversidade Católica do Paraná, Curitiba, Brazil.
  • Gogna R; Complexo Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil.
  • Madan E; Pontifical Catholic University of Parana, Curitiba, Brazil.
  • Alizadeh-Navaei R; Pontifical Catholic University of Parana, Curitiba, Brazil.
  • Lamperti L; Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Zuñiga F; Molecular and Cell Biology Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Nova-Lamperti E; Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Labarca G; Gastrointestinal Cancer Research Centre, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Knippenberg B; Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
  • Herwanto V; Novo Nordisk Foundation centre for Stem Cell Biology, DanStem, Faculty of Health and Medical Sciences, Champalimaud Centre for the Unknown, Lisbon, Portugal.
  • Wang Y; Campania Centre for the Unknown, Lisbon, Portugal.
  • Phu A; Gastrointestinal Cancer Research Centre, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Chew T; Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepcion, Concepcion, Chile.
  • Kwan T; Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepcion, Concepcion, Chile.
  • Kim K; Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepcion, Concepcion, Chile.
  • Teoh S; Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepcion, Concepcion, Chile.
  • Pelaia TM; Faculty of Medicine, Universidad de Concepcion, Concepcion, Chile.
  • Kuan WS; Infectious Diseases Department, Royal Darwin Hospital, Darwin, NT, Australia.
  • Jee Y; Faculty of Medicine, Universitas Tarumanagara, Jakarta, Indonesia.
  • Iredell J; Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia.
  • O'Byrne K; Centre for Immunology and Allergy Research, the Westmead Institute for Medical Research, Westmead, NSW, Australia.
  • Fraser JF; Department of Medicine, Sydney Medical School Nepean, Nepean Hospital, University of Sydney, Penrith, NSW, Australia.
Front Immunol ; 13: 1060438, 2022.
Article in English | MEDLINE | ID: covidwho-2235597
ABSTRACT

Purpose:

Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness.

Methods:

We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 (IFI27) in COVID-19 patients.

Results:

We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression in the lower respiratory tract is associated with the presence of a high viral load. We further demonstrate that the systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 infection. For clinical outcome prediction (e.g., respiratory failure), IFI27 expression displays a high sensitivity (0.95) and specificity (0.83), outperforming other known predictors of COVID-19 outcomes. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 influenza virus infection, IFI27-like genes were highly upregulated in the blood samples of severely infected patients.

Conclusion:

These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza, Human / Influenza A Virus, H1N1 Subtype / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1060438

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza, Human / Influenza A Virus, H1N1 Subtype / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1060438